Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01891981 · ClinicalTrials.gov registry record · Phase 1
Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01891981: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01891981 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01891981, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of moxetumomab pasudotox that can be given to patients with relapsed and/or refractory ALL.
Interventions
- DRUG Moxetumomab Pasudotox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-12-17 |
| Est. Completion | 2017-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01891981
The ClinicalTrials.gov registry entry for NCT01891981 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Moxetumomab Pasudotox is the first listed.
NCT01891981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01891981 about?
NCT01891981 is a clinical study titled "Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)". The goal of this clinical research study is to find the highest tolerable dose of moxetumomab pasudotox that can be given to patients with relapsed and/or refractory ALL.
What is the current status of trial NCT01891981?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2013-12-17. Estimated completion is 2017-04-12.
What interventions are being tested in trial NCT01891981?
The interventions under investigation include: Moxetumomab Pasudotox (DRUG).
Who is sponsoring clinical trial NCT01891981?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.